Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by str8tgoodson Oct 29, 2010 1:10pm

550 Views

Post# 17631287

RE: Level 2 Quote

Just got to get rid of that wall at 24 cents. Doubt it will happen today, but you never know. Next week should be a different story though.

Don't want this to go hyperbolic before the news. Hopefully it will only take 4 weeks instead of 6 weeks, but you just can't know for sure with testing. Trading is very positive though, so let's hope results are too. GLTA

Level ll Quote
Bid			Ask
Price	Total Size	# of Orders	Price	Total Size	# of Orders

.23	349	14	.235	98	2
.225	398	10	.24	1103	16
.22	267	13	.245	640	9
.215	261	6	.25	337	11
.21	665	20	.255	140	3
.205	76	6	.26	79	4
.20	524	17	.27	20	1
.195	655	6	.275	221	3
.19	462	16	.28	13	2
.185	32	1	.285	30	1